Androgenic alopecia
Conditions
Interventions
Treated group:Treatment area injections of autologous adipose stem cell-enriched matrix components
Control group:None
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 to 50 years old; Male and female. 2. Primary alopecia with a disease duration of more than 1 year. 3. It conforms to the BASP classification system, and it is one of M2 type, M3 type, C2 type, C3 type, F2 type, and F3 type.
Exclusion criteria
Exclusion criteria: 1. Past medical history that meets any of the following criteria: received topical androgen-derived alopecia therapy (such as topical hormones, anti-androgen-derived alopecia) within 6 months; or treatment for systemic androgen-derived alopecia (e.g., oral anti-androgen-derived drugs) within 1 year; or those who have previously undergone autologous hair transplant surgery. 2. There are other factors that can be traced to cause hair loss, such as postpartum alopecia, alopecia areata, cicatricial alopecia, etc., and the symptoms of hair loss secondary to other diseases are excluded. 3. Conform to the categories other than M2, M3, C2, C3, F2 and F3 in the BASP classification. 4. According to laboratory tests and other clinical signs and symptoms, the investigator judged that the subject had abnormal blood routine, coagulation function, liver and kidney function. 5. There is a risk of infection in the injection area that is not suitable for injection, such as folliculitis, fungal infection, ulceration, etc.; 6. Patients with serious medical diseases (such as diabetes, hepatitis, coronary heart disease, arteriosclerosis, glomerulonephritis, hematologic diseases, autoimmune diseases, etc.) and a history of malignant tumors in the past; 7. Those who have quit smoking for less than 3 months; 8. Those who have mental illness, lack of self-awareness, and cannot accurately express themselves and cooperate; 9. Patients who are not suitable for liposuction as assessed by a doctor; 10. Those who have participated in other clinical trials within 30 days before the screening visit of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dermoscopic terminal hair/vellus hair ratio at week 12 after initial treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermoscopic terminal hair/vellus hair ratio at weeks 6, 18 and 24 after initial treatment;Hair density at weeks 6, 12, 18 and 24 after initial treatment;Self-assessment of the GAIS scale in patients at weeks 6, 12, 18 and 24 after initial treatment;The GAIS scale evaluated by the researcher at weeks 6, 12, 18 and 24 after initial treatment;Patients completed a questionnaire at week 24 post-treatment to rate their satisfaction with the treatment; | — |
Countries
China
Contacts
Public ContactZhou Shuangbai
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed